Healthcare
Based on ARK ETF real-time + 13F quarterly filings
13F data may be delayed up to 90 days.
※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.
Absci Corporation is a data-first generative AI drug creation company that uses AI and wet lab technologies to design antibody therapeutics. Their preclinical programs target various conditions including inflammatory bowel disease, alopecia, and oncology. Absci collaborates with several partners for joint research and development.
AI-generated summary. Not investment advice.